See related article, p 230, 233, 240, 249 and 257 S ickle cell disease (SCD) is the most common hemoglobinopathy worldwide, with over 300 000 children born with SCD each year. 1 Neurological consequences of SCD include ischemic and hemorrhagic strokes 2 and cognitive deficits. 3 SCD accounts for almost 1 out of 4 of all stroke-related hospitalizations in black children. 4 Historically, ischemic stroke in SCD has been separated by symptomatology, including "overt stroke," referring to radiographic ischemia with associated neurological deficits detectable on a bedside examination and "silent stroke" referring to radiographic ischemia without focal neurological deficits, but associated with cognitive deficits. However, this dichotomy is likely false, as the two can be radiographically indistinguishable. 5 Strokes may have lifelong devastating consequences, including limited educational attainment and decreased quality of life in children. 6, 7 Sickle cell anemia refers to the most severe SCD phenotypes, SS and Sβ 0 thalassemia, which have the highest stroke incidence. However, other SCD genotypes are also at risk for cerebral ischemia, with up to 13% of hemoglobin SC children having silent ischemia on screening magnetic resonance imaging (MRI). 2, 8 Transcranial Doppler (TCD) screening to identify children with SCD at highest stroke risk combined with primary stroke prevention with chronic transfusion therapy (CTT) revolutionized pediatric sickle cell stroke management in the 1990s. Despite the dramatic reduction of "overt strokes" through CTT shown in the STOP trial (Stroke Prevention Trial in Sickle Cell Anemia), children with SCD remain at high risk of stroke (Figure) . 2, [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] Clinical and translational research in the post-STOP era have increased our understanding of the multifactorial complexity of stroke in children with SCD (Table 1) . Recent work has demonstrated how components of the cerebral metabolic rate of oxygen utilization contribute to ischemia in SCD. Cerebral metabolic rate of oxygen utilization is the product of cerebral blood flow (CBF), arterial oxygen content (CaO 2 ). and oxygen extraction fraction (OEF). CBF and CaO 2 comprise cerebral oxygen delivery, and OEF quantifies the transfer of available oxygen supply into the brain tissue. Ischemia occurs when cerebral metabolic rate of oxygen utilization does not meet the metabolic demands and falls below the threshold of tissue viability. 26 Here, we will review advances in causal pathways of ischemic stroke and therapy options.
Oxygen Content
Decreased CaO 2 in SCD can result from anemia, hypoxia, and the altered oxygen delivery of hemoglobin (Hb) S. Severe anemia is associated with acute cerebral ischemia in children with and without SCD. 27 CaO 2 depends not only on the amount of hemoglobin (lowered by hemolysis or red blood cell sequestration), but also the percent saturated, commonly measured by pulse oximetry (SpO 2 ). Oxygen saturation may be transiently or persistently decreased in SCD; possible mechanisms include rightward shifting of the oxygen desaturation curve, 28 nocturnal desaturation during sleep, 29, 30 presence of a right-to-left shunt at the cardiac or pulmonary level, 31 or lung pathology, such as acute chest syndrome. Lower steady-state daytime SpO 2 increases risk of infarction, with the odds ratio for "overt stroke" increasing by 1.32 for each 1% decrease in pulse oximetry value. 32 Lower SpO 2 is also associated with increased blood flow velocity, as measured by TCD, 33 and microstructural white matter abnormalities. 34 Upper airway obstruction and obstructive sleep apnea correlate with increased risk of neurological complications. 35 Adenotonsillectomy improves TCD velocities 36 and is cost-effective in SCD because of decreased visits for cerebral ischemic events.
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Chronic Transfusion Therapy
A direct way to increase CaO 2 is through red cell transfusion, which increases total hemoglobin and decreases HbS%. Early studies of CTT, with dual goals of transfusing to keep Hb >10 gm/dL and HbS <30%, demonstrated dramatic secondary stroke prevention. 38 Subsequent studies have used variations of these initial goals, and current guidelines simplify recommendations to keep HbS <30% for primary and secondary stroke prevention, as this has been most commonly used in trials. However, no studies have compared outcomes of differing transfusion goals. 39 CTT is associated with alloimmunization, transfusion reactions, iron overload, increased thrombotic risk with central line placement, and increased mortality. 40, 41 Careful monitoring is required to minimize complications. Furthermore, CTT has academic and socioeconomic consequences because of missed school and work days.
Multiple studies have sought to determine whether CTT is only needed for a high-risk period, or if patients may be 
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transitioned to other stroke prevention strategies, thereby limiting morbidity. STOP-2 (Optimizing Primary Stroke Prevention in SCA) randomized children to discontinue CTT when TCD normalized but was terminated early because of non-CTT cohort reverting to high-risk TCD velocities or experiencing new strokes. 22 The SWiTCH trial (Stroke With Transfusions Changing to Hydroxyurea) sought to determine whether hydroxyurea paired with phlebotomy could be as effective as CTT paired with chelation in children on stable CTT. The composite primary end point was secondary stroke recurrence rate and quantitative liver iron overload. The study was closed at interim analysis because of an inability to meet the end point; there was no difference in liver iron concentration between the 2 cohorts, and 7 new strokes occurred within the hydroxyurea arm. 23 Follow-up imaging analyses from the SWiTCH trial found a high incidence of vasculopathy (58% and 46% on the left and right, respectively). Of note, all 7 participants that had a stroke during the trial had vasculopathy. 42 Lifelong CTT remains the only proven strategy for secondary "overt stroke" prevention. Although CTT is the most effective intervention for secondary stroke prevention, up to 45% of children on CTT may still experience ischemic events. 16 Children with vasculopathy and without any clear physiological stressor (ie, acute chest, acute anemia) proximal to the initial stroke seem to have the highest recurrence rate. 16, 18 The SIT trial (Silent Cerebral Infarct Multi-Center Clinical Trial aka Silent Infarct Transfusion), sought to extrapolate the benefits of CTT in the "overt stroke" population to the "silent stroke" population. 17 Silent infarcts also carry neurological morbidity, demonstrate a high rate of recurrence, and increase risk of "overt stroke." 43 Of the 1074 children screened, silent infarcts were found in 379 (35%), and 196 were randomized to transfusions or standard care. The study demonstrated a 58% relative risk reduction in infarct recurrence, but with a number needed to treat NNT of 13 over 3 years to prevent one infarct, the perceived risk-benefit may differ among families. 17 Although CTT is not currently widespread standard of care for secondary "silent stroke" prevention, these results warrant in-depth discussions with families to reach shared decision making in balancing the risks of CTT with the risks of further infarcts.
Hydroxyurea
Hydroxyurea is a ribonucleotide reductase inhibitor that increases hemoglobin, and thereby CaO 2 , via an increase in hemoglobin F production, in addition to counteracting the downstream effects of sickling and hemolysis by decreasing white blood cell and platelet counts and increasing nitric oxide. 44 In 1995, hydroxyurea was first shown to be clinically effective in adults with a decrease in painful events, acute chest syndrome, red blood cell transfusions, and mortality. 45 In 1998, the Food and Drug Administration approved its use in adults with SCD. The HUG-KIDS Study (Predicting Early Mortality From Ischemic Stroke) provided Phase I/II data in children shortly thereafter in 1999. 46 This led to recommendations for all children with SCA to be offered hydroxyurea therapy by 9 months of age in the National Heart Lung Blood Institute 2014 Evidence-Based Report 39 and Food and Drug Administration approval for children with SCD in 2017.
The role of hydroxyurea in primary stroke prevention warrants further investigation, but the available data are promising in specific clinical scenarios. The BABY HUG trial (Pediatric Hydroxyurea Phase III Clinical Trial), the first randomized, double-blind trial of hydroxyurea in children with SCD, found that the increase in TCD velocities from study entry to exit was significantly lower in the cohort of children receiving hydroxyurea therapy when compared with those receiving placebo. 47 Data from Nigeria suggests that hydroxyurea can be used for primary stroke prevention in patients with elevated TCD velocities ≥170 cm/s living in environments lacking resources for CTT. 48 Even though the phase III multicenter, international SCATE trial (Sparing Conversion to Abnormal TCD Elevation) closed early because of slow accrual, the data suggests that hydroxyurea can prevent conversion to an abnormal TCD, potentially avoiding the need for CTT. 25 A retrospective study also showed a higher percentage of TCD velocity improvement in those receiving hydroxyurea compared with those without intervention. 49 For patients on CTT for primary stroke prophylaxis because of elevated TCDs, results of the phase 3, noninferiority TWiTCH trial (TCD With Transfusions Changing to Hydroxyurea) found that in children who had received at least 12 months of CTT, hydroxyurea maintained equivalent TCD as they had achieved on CTT. Of note, patients with vasculopathy were excluded from the TWiTCH trial; hence, data does not currently support the use of hydroxyurea for primary stroke prevention in the subgroup of SCD patients with vasculopathy. 24 As noted above, the SWiTCH study demonstrated that hydroxyurea cannot be recommended for secondary "overt stroke" prevention. 23 The role of hydroxyurea for SCI prevention remains unclear. Participants receiving hydroxyurea therapy in the prospective, observational HUSTLE (Hydroxyurea Study of Long-Term Effects) did not develop new or enlarging SCIs at the rate one would expect per the natural history of the disease. 50 Comparison of HUSTLE to SIT data suggest hydroxyurea may be effective for recurrent SCI prevention 51 
Expanding Hydroxyurea Indications for Stroke Prevention
With TWiTCH demonstrating a subset of children on CTT who may safely transition to hydroxyurea without apparent increased risk, future work may include identifying other CTT populations, such as those without vasculopathy who had an acute concurrent medical event before their stroke, 18 who may also be able to successfully transition off CTT to hydroxyurea. Safe alternatives to CTT are needed because the majority of the world's SCD population lives in low-income countries, 1 and, therefore, implementation of lifelong CTT may exceed locally available resources.
Recent studies have focused on translating knowledge gained from high-resource countries to stroke prevention strategies in Africa. Hydroxyurea has been demonstrated to lower TCD in an African cohort, 48 but maximal dosing of hydroxyurea requires resources for monitoring dosing and toxicity. 46 Currently 
Cerebral Blood Flow
The relationship between CBF and ischemic stroke in SCD has long been recognized but remains incompletely understood. Quantitative CBF is the total volume of blood measured per minute, normalized to 100 g of brain tissue. Ford et al 55 recently demonstrated that regions of lowest CBF correspond to areas of highest frequency of silent cerebral infarct in children with SCD. Adams et al 56 demonstrated correlation between high TCD values and "overt stroke" risk. TCD measures only the speed of blood passing through the major cerebral arteries, and values are typically reported as centimeters per second. CBF and TCD do not directly correlate without conversion of the TCD velocity to CBF units, based on arterial size and estimation of tissue weight supplied by the artery, both of which require MRI measurements. 57 TCDs are portable and noninvasive, but limitations include high operator-dependence, inability to detect velocities in all patients, particularly those with poor bone windows, a low specificity for stroke, 56 and they do not predict silent ischemia. TCD does not have direct correlation with underlying vascular abnormalities, but stenosis may influence TCD values by either raising or significantly lowering velocities. 58 Hematocrit and SpO 2 (ie, CaO 2 ), as well as age, have been correlated with TCD values. 33 Of note, initial studies used nonimaging TCDs, and imaging TCD systems provide values ≈10% lower than nonimaging, so thresholds should be adjusted based upon the system. 59 Multiple MRI modalities are capable of measuring CBF with various pros and cons to each technique. 60 Cerebral internal carotid artery and middle cerebral artery luminal area are increased in SCD, 61 and CBF is elevated in children with SCD compared with controls. 62, 63 Vasodilatory autoregulation of the cerebral vasculature allows for the brain to titrate blood flow based on metabolic demand and arterial oxygen supply. CBF values inversely correlate with hemoglobin and CaO 2 , 62,64,65 and transfusions decrease CBF. Severe anemia may push cerebral vasculature to maximal compensation, such that the drive to maintain oxygen delivery overrides the vasculature's usual sensitivity to other factors, such as carbon dioxide. Kosinski et al 66 recently demonstrated that the cerebral reactivity reserve is lost with severe anemia of SCD but can be restored with the increased Hb from transfusion.
Vasculopathy
The field has been plagued by inconsistent use of the term vasculopathy in the literature, which creates challenges for direct comparisons of studies (Table 2) . Future endeavors should work to unify definitions, possibly with non-SCD pediatric arteriopathy scales. 71 Despite the wide array of definitions, vasculopathy is consistently associated with an increased risk of ischemia in SCD. Presumably through limitation of CBF, vasculopathy is associated with ischemia, 68 stroke recurrence, 16, 23, 42 and distal atrophy. 70 Autopsy studies demonstrate intimal hyperplasia and mural thrombi. 72, 73 The degree of anemia may contribute chronic exposure to shear stress, and through improved total hemoglobin, hydroxyurea may slow or potentially prevent development of vasculopathy. Vasculopathy occurs in 12% to 23% of children with SCD 14, 67 ; reasons for incomplete penetrance remain poorly understood. Genetic factors almost certainly play a role as well, including glucose-6-phosphate dehydrogenase (G6PD), 68 although G6PD has not been found to have an association with overall stroke risk. 74, 75 Moyamoya angiopathy is a severe form of vasculopathy with progressive occlusion of one or both internal carotid arteries commonly associated with collateral vessel growth, which can occur in children with and without SCD. Surgical revascularization provides alternative blood supply through either direct bypass or, more commonly in children, indirect procedures which improve CBF and decrease ischemic events in children without SCD. 76, 77 Similarly, children with SCD, may also have decreased ischemic events after indirect revascularization surgery, regardless of the method used, with several studies reporting zero further ischemic events in the postsurgery follow-up period. [78] [79] [80] [81] Although Winstead et al 82 reported that 3 out of 7 SCD children with moyamoya who underwent surgery did not have successful revascularization with flow through the graft, an important detail is that 2 children were managed on concomitant CTT and hydroxyurea, although details of the timing of hydroxyurea and revascularization surgery are not provided. As hydroxyurea inhibits angiogenesis, 83, 84 it is imperative that these 2 stroke reduction management strategies not be used simultaneously in children with SCD. This must also be remembered as hydroxyurea is commonly used in preparation for stem-cell transplantation (SCT), warranting careful multidisciplinary discussion about timing of for stem-cell transplantation postrevascularization. At our institutions, we attempt to hold hydroxyurea (and thus for stem-cell transplantation) for 6 to 12 months postrevascularization to maximize surgical benefit.
Oxygen Extraction
The OEF reflects the amount of oxygen that diffuses from the bloodstream into tissue. An increased OEF, reflective of a decrease of oxygen content or CBF, or increased cerebral metabolic rate of oxygen utilization, heralds stroke risk in non-SCD adults. 85 Historically, OEF was measured with positron emission tomography, but more recent techniques enable measurement with MRI, thus sparing radiation exposure. 86, 87 MRI techniques have demonstrated an increase in global OEF in SCD, 88, 89 as well as regionally elevated OEF in the borderzone region of children with SCD, 63 and decreases in the volume of regions with highest OEF with transfusion. 90 Work is needed to determine whether MRI-measured OEF may serve as a screening option to predict ischemia in children with SCD, and even more work is needed to translate OEF into clinical practice to optimize CTT, such as decreasing transfusion frequency or individualizing HbS% goal, if
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OEF successfully predicts stroke risk. However, recent studies and broad interest in the field suggests OEF holds promise for advancing precision medicine in SCD.
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Conclusions
Stroke in SCD is multifactorial and complex, and there have been significant physiological and clinical advances in recent years. Future directions will include recognition of different causes of ischemic stroke and efforts toward decreasing the transfusion burden, either through identifying further children who may safely transition to other therapies or through individualization of CTT. An increased appreciation for the role of vasculopathy should lead to more investigation of therapies commonly used in other populations with vasculopathy, including antiplatelet agents and revascularization. Primary and secondary stroke prevention in SCD has greatly improved over the past decades, but further work is needed to continue to reduce stroke in SCD around the world. 
